TDMS Study 05212-04 Pathology Tables
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus OXAZEPAM DATE: 09/18/94
EXPERIMENT: 05212 TEST: 04 TIME: 12:07:43
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE PAGE: 1
CONT: NO1ES85213 ROUTE: DOSED FEED NTP C#: 062453
PATHOLOGIST: M. RYAN HAILEY, JAMESR. CAS: 604-75-1
------------------------------------------------------------------------------------------------------------------------------------
REASONS FOR REMOVAL: ALL
REMOVAL DATE RANGE: ALL
TREATMENT GROUPS: INCLUDE ALL
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus OXAZEPAM DATE: 09/18/94
EXPERIMENT: 05212 TEST: 04 TIME: 12:07:43
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: NO1ES85213 ROUTE: DOSED FEED NTP C#: 062453
PATHOLOGIST: M. RYAN HAILEY, JAMESR. CAS: 604-75-1
35( )
----------------------------
FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED.
IN OTHER TISSUES/ORGANS, RATES ARE BASED ON NUMBER OF ANIMALS NECROPSIED.
----------------
Adrenal Cortex
Adrenal Medulla
Bone Marrow
Brain
Clitoral Gland
Epididymis
Gallbladder
Heart
Islets, Pancreatic
Kidney
Liver
Lung
Nose
Ovary
Pancreas
Parathyroid Gland
Pituitary Gland
Preputial Gland
Prostate
Salivary Glands
Spleen
Testes
Thymus
Thyroid Gland
Urinary Bladder
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus OXAZEPAM DATE: 09/18/94
EXPERIMENT: 05212 TEST: 04 TIME: 12:07:43
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: NO1ES85213 ROUTE: DOSED FEED NTP C#: 062453
PATHOLOGIST: M. RYAN HAILEY, JAMESR. CAS: 604-75-1
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF THE STUDY OF OXAZEPAM
====================================================================================================
MALE MICE
-------------
ORGAN MORPHOLOGY
------- ------------
Liver Hepatocellular Adenoma
Hepatocellular Carcinoma
Hepatocellular Carcinoma or Hepatoblastoma
Hepatocellular Carcinoma or Hepatocellular Adenoma
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma
Lung Alveolar/Bronchiolar Carcinoma
All Organs Malignant Lymphoma And Histiocytic Sarcoma
Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed,
NOS, or Undifferentiated Cell Type
Benign Tumors
Malignant Tumors
Malignant and Benign Tumors
====================================================================================================
FEMALE MICE
-------------
ORGAN MORPHOLOGY
------- ------------
Liver Hepatocellular Adenoma
Hepatocellular Carcinoma
Hepatocellular Carcinoma or Hepatoblastoma
Hepatocellular Carcinoma or Hepatocellular Adenoma
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma
All Organs Malignant Lymphoma And Histiocytic Sarcoma
Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed,
NOS, or Undifferentiated Cell Type
Benign Tumors
Malignant Tumors
Malignant and Benign Tumors
====================================================================================================
DATE: 09/18/94 EXPERIMENT: 05212 TEST: 04 PAGE 1
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN 35( ) -- OXAZEPAM
TERMINAL SACRIFICE AT 57 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 PPM 2500 PPM 5000 PPM | 0 PPM 2500 PPM 5000 PPM |
| | | |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/60 (2%) 35/60 (58%) 50/60 (83%) | 0/60 (0%) 22/59 (37%) 47/59 (80%) |
|ADJUSTED (b) | 2.2% 88.7% 98.0% | 0.0% 52.6% 95.7% |
|TERMINAL (d) | 1/45 (2%) 15/19 (79%) 9/10 (90%) | 0/47 (0%) 10/28 (36%) 15/17 (88%) |
|FIRST INCIDENCE (DAYS) | 397 (T) 268 231 | --- 291 284 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|INCIDENTAL TUMOR | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|COCHRAN-ARMITAGE | P<0.001 ** | P<0.001 ** |
|FISHER EXACT | P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/60 (0%) 5/60 (8%) 19/60 (32%) | 1/60 (2%) 1/59 (2%) 11/59 (19%) |
|ADJUSTED (b) | 0.0% 21.7% 72.0% | 2.1% 3.6% 51.6% |
|TERMINAL (d) | 0/45 (0%) 3/19 (16%) 5/10 (50%) | 1/47 (2%) 1/28 (4%) 8/17 (47%) |
|FIRST INCIDENCE (DAYS) | --- 356 302 | 397 (T) 397 (T) 337 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P=0.003 ** P<0.001 ** | P<0.001 ** P=0.642 P<0.001 ** |
|INCIDENTAL TUMOR | P<0.001 ** P=0.017 * P<0.001 ** | P<0.001 ** P=0.642 P<0.001 ** |
|LOGISTIC REGRESSION | P<0.001 ** P=0.010 * P<0.001 ** | P<0.001 ** P=0.642 P<0.001 ** |
|COCHRAN-ARMITAGE | P<0.001 ** | P<0.001 ** |
|FISHER EXACT | P=0.029 * P<0.001 ** | P=0.748 P=0.002 ** |
|=================================================================================================================================|
DATE: 09/18/94 EXPERIMENT: 05212 TEST: 04 PAGE 2
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN 35( ) -- OXAZEPAM
TERMINAL SACRIFICE AT 57 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 PPM 2500 PPM 5000 PPM | 0 PPM 2500 PPM 5000 PPM |
| | | |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma or Hepatoblastoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/60 (0%) 5/60 (8%) 19/60 (32%) | 1/60 (2%) 1/59 (2%) 11/59 (19%) |
|ADJUSTED (b) | 0.0% 21.7% 72.0% | 2.1% 3.6% 51.6% |
|TERMINAL (d) | 0/45 (0%) 3/19 (16%) 5/10 (50%) | 1/47 (2%) 1/28 (4%) 8/17 (47%) |
|FIRST INCIDENCE (DAYS) | --- 356 302 | 397 (T) 397 (T) 337 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P=0.003 ** P<0.001 ** | P<0.001 ** P=0.642 P<0.001 ** |
|INCIDENTAL TUMOR | P<0.001 ** P=0.017 * P<0.001 ** | P<0.001 ** P=0.642 P<0.001 ** |
|LOGISTIC REGRESSION | P<0.001 ** P=0.010 * P<0.001 ** | P<0.001 ** P=0.642 P<0.001 ** |
|COCHRAN-ARMITAGE | P<0.001 ** | P<0.001 ** |
|FISHER EXACT | P=0.029 * P<0.001 ** | P=0.748 P=0.002 ** |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma or Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/60 (2%) 35/60 (58%) 52/60 (87%) | 1/60 (2%) 23/59 (39%) 47/59 (80%) |
|ADJUSTED (b) | 2.2% 88.7% 98.1% | 2.1% 55.2% 95.7% |
|TERMINAL (d) | 1/45 (2%) 15/19 (79%) 9/10 (90%) | 1/47 (2%) 11/28 (39%) 15/17 (88%) |
|FIRST INCIDENCE (DAYS) | 397 (T) 268 231 | 397 (T) 291 284 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|INCIDENTAL TUMOR | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|COCHRAN-ARMITAGE | P<0.001 ** | P<0.001 ** |
|FISHER EXACT | P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** |
|=================================================================================================================================|
DATE: 09/18/94 EXPERIMENT: 05212 TEST: 04 PAGE 3
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN 35( ) -- OXAZEPAM
TERMINAL SACRIFICE AT 57 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 PPM 2500 PPM 5000 PPM | 0 PPM 2500 PPM 5000 PPM |
| | | |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/60 (2%) 35/60 (58%) 52/60 (87%) | 1/60 (2%) 23/59 (39%) 47/59 (80%) |
|ADJUSTED (b) | 2.2% 88.7% 98.1% | 2.1% 55.2% 95.7% |
|TERMINAL (d) | 1/45 (2%) 15/19 (79%) 9/10 (90%) | 1/47 (2%) 11/28 (39%) 15/17 (88%) |
|FIRST INCIDENCE (DAYS) | 397 (T) 268 231 | 397 (T) 291 284 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|INCIDENTAL TUMOR | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|COCHRAN-ARMITAGE | P<0.001 ** | P<0.001 ** |
|FISHER EXACT | P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 12/60 (20%) 6/60 (10%) 7/60 (12%) | 6/60 (10%) 4/59 (7%) 6/59 (10%) |
|ADJUSTED (b) | 26.7% 28.9% 26.0% | 12.8% 12.4% 24.2% |
|TERMINAL (d) | 12/45 (27%) 5/19 (26%) 0/10 (0%) | 6/47 (13%) 3/28 (11%) 2/17 (12%) |
|FIRST INCIDENCE (DAYS) | 397 (T) 369 272 | 397 (T) 294 325 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.123 P=0.482 P=0.164 | P=0.103 P=0.593 P=0.105 |
|INCIDENTAL TUMOR | P=0.538N P=0.606 P=0.406N | P=0.305 P=0.609N P=0.389 |
|LOGISTIC REGRESSION | P=0.353N P=0.570N P=0.329N | P=0.385 P=0.515N P=0.393 |
|COCHRAN-ARMITAGE | P=0.117N | P=0.552 |
|FISHER EXACT | P=0.100N P=0.159N | P=0.382N P=0.607 |
|=================================================================================================================================|
DATE: 09/18/94 EXPERIMENT: 05212 TEST: 04 PAGE 4
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN 35( ) -- OXAZEPAM
TERMINAL SACRIFICE AT 57 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 PPM 2500 PPM 5000 PPM | 0 PPM 2500 PPM 5000 PPM |
| | | |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 5/60 (8%) 4/60 (7%) 0/60 (0%) | 5/60 (8%) 3/59 (5%) 1/59 (2%) |
|ADJUSTED (b) | 10.5% 14.2% 0.0% | 10.6% 8.9% 2.6% |
|TERMINAL (d) | 4/45 (9%) 1/19 (5%) 0/10 (0%) | 5/47 (11%) 2/28 (7%) 0/17 (0%) |
|FIRST INCIDENCE (DAYS) | 281 268 --- | 397 (T) 294 342 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.266N P=0.407 P=0.217N | P=0.317N P=0.620N P=0.413N |
|INCIDENTAL TUMOR | P=0.033N* P=0.444N P=0.139N | P=0.186N P=0.544N P=0.274N |
|LOGISTIC REGRESSION | P=0.043N* P=0.551N P=0.051N | P=0.111N P=0.458N P=0.213N |
|COCHRAN-ARMITAGE | P=0.030N* | P=0.074N |
|FISHER EXACT | P=0.500N P=0.029N* | P=0.368N P=0.107N |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 14/60 (23%) 9/60 (15%) 7/60 (12%) | 11/60 (18%) 6/59 (10%) 7/59 (12%) |
|ADJUSTED (b) | 30.2% 35.7% 26.0% | 23.4% 19.4% 26.2% |
|TERMINAL (d) | 13/45 (29%) 5/19 (26%) 0/10 (0%) | 11/47 (23%) 5/28 (18%) 2/17 (12%) |
|FIRST INCIDENCE (DAYS) | 281 268 272 | 397 (T) 294 325 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.200 P=0.291 P=0.286 | P=0.266 P=0.510N P=0.259 |
|INCIDENTAL TUMOR | P=0.203N P=0.514N P=0.216N | P=0.545N P=0.452N P=0.567N |
|LOGISTIC REGRESSION | P=0.158N P=0.415N P=0.155N | P=0.407N P=0.346N P=0.506N |
|COCHRAN-ARMITAGE | P=0.056N | P=0.183N |
|FISHER EXACT | P=0.177N P=0.074N | P=0.156N P=0.234N |
|=================================================================================================================================|
DATE: 09/18/94 EXPERIMENT: 05212 TEST: 04 PAGE 5
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN 35( ) -- OXAZEPAM
TERMINAL SACRIFICE AT 57 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 PPM 2500 PPM 5000 PPM | 0 PPM 2500 PPM 5000 PPM |
| | | |
|=================================================================================================================================|
| |
|Uterus |
| Sarcoma Stromal or Polyp Stromal |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | # # # |
|----------- | | |
|OVERALL (a) | | 2/60 (3%) 0/59 (0%) 1/59 (2%) |
|ADJUSTED (b) | | 3.7% 0.0% 5.9% |
|TERMINAL (d) | | 0/47 (0%) 0/28 (0%) 1/17 (6%) |
|FIRST INCIDENCE (DAYS) | | 322 --- 397 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.527N P=0.309N P=0.699N |
|INCIDENTAL TUMOR | | P=0.270N P=0.095N P=0.372N |
|LOGISTIC REGRESSION | | P=0.361N P=0.200N P=0.485N |
|COCHRAN-ARMITAGE | | P=0.365N |
|FISHER EXACT | | P=0.252N P=0.506N |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma And Histiocytic Sarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 10/60 (17%) 7/60 (12%) 6/60 (10%) | 9/60 (15%) 13/59 (22%) 7/59 (12%) |
|ADJUSTED (b) | 17.6% 13.9% 28.3% | 15.4% 26.2% 17.9% |
|TERMINAL (d) | 0/45 (0%) 0/19 (0%) 2/10 (20%) | 0/47 (0%) 2/28 (7%) 1/17 (6%) |
|FIRST INCIDENCE (DAYS) | 244 145 272 | 184 106 197 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.415N P=0.435N P=0.519N | P=0.447 P=0.117 P=0.516 |
|INCIDENTAL TUMOR | P=0.002N** P=0.002N** P=0.002N** | P=0.002N** P=0.144N P=0.002N** |
|LOGISTIC REGRESSION | P=0.005N** P=0.036N* P=0.007N** | P=0.017N* P=0.260N P=0.056N |
|COCHRAN-ARMITAGE | P=0.169N | P=0.370N |
|FISHER EXACT | P=0.301N P=0.211N | P=0.226 P=0.409N |
|=================================================================================================================================|
DATE: 09/18/94 EXPERIMENT: 05212 TEST: 04 PAGE 6
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN 35( ) -- OXAZEPAM
TERMINAL SACRIFICE AT 57 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 PPM 2500 PPM 5000 PPM | 0 PPM 2500 PPM 5000 PPM |
| | | |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, |
| NOS, or Undifferentiated Cell Type |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 9/60 (15%) 7/60 (12%) 6/60 (10%) | 9/60 (15%) 13/59 (22%) 6/59 (10%) |
|ADJUSTED (b) | 16.0% 13.9% 28.3% | 15.4% 26.2% 16.1% |
|TERMINAL (d) | 0/45 (0%) 0/19 (0%) 2/10 (20%) | 0/47 (0%) 2/28 (7%) 1/17 (6%) |
|FIRST INCIDENCE (DAYS) | 244 145 272 | 184 106 197 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.508N P=0.526N P=0.603 | P=0.543 P=0.117 P=0.581N |
|INCIDENTAL TUMOR | P=0.007N** P=0.006N** P=0.007N** | P<0.001N** P=0.144N P=0.001N** |
|LOGISTIC REGRESSION | P=0.014N* P=0.080N P=0.021N* | P=0.010N** P=0.260N P=0.036N* |
|COCHRAN-ARMITAGE | P=0.243N | P=0.278N |
|FISHER EXACT | P=0.395N P=0.291N | P=0.226 P=0.303N |
|=================================================================================================================================|
| |
|All Organs |
| Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 14/60 (23%) 36/60 (60%) 51/60 (85%) | 9/60 (15%) 26/59 (44%) 47/59 (80%) |
|ADJUSTED (b) | 30.4% 91.5% 98.0% | 18.5% 61.2% 95.7% |
|TERMINAL (d) | 13/45 (29%) 16/19 (84%) 9/10 (90%) | 8/47 (17%) 13/28 (46%) 15/17 (88%) |
|FIRST INCIDENCE (DAYS) | 344 268 231 | 322 291 284 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|INCIDENTAL TUMOR | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|COCHRAN-ARMITAGE | P<0.001 ** | P<0.001 ** |
|FISHER EXACT | P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** |
|=================================================================================================================================|
DATE: 09/18/94 EXPERIMENT: 05212 TEST: 04 PAGE 7
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN 35( ) -- OXAZEPAM
TERMINAL SACRIFICE AT 57 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 PPM 2500 PPM 5000 PPM | 0 PPM 2500 PPM 5000 PPM |
| | | |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 17/60 (28%) 17/60 (28%) 25/60 (42%) | 16/60 (27%) 16/59 (27%) 17/59 (29%) |
|ADJUSTED (b) | 29.6% 44.1% 80.3% | 27.7% 34.7% 61.0% |
|TERMINAL (d) | 5/45 (11%) 4/19 (21%) 6/10 (60%) | 6/47 (13%) 5/28 (18%) 9/17 (53%) |
|FIRST INCIDENCE (DAYS) | 244 145 271 | 184 106 197 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P=0.170 P<0.001 ** | P=0.037 * P=0.230 P=0.025 * |
|INCIDENTAL TUMOR | P=0.495 P=0.053N P=0.439N | P=0.313N P=0.102N P=0.452N |
|LOGISTIC REGRESSION | P=0.321 P=0.203N P=0.555 | P=0.390N P=0.236N P=0.427N |
|COCHRAN-ARMITAGE | P=0.072 | P=0.437 |
|FISHER EXACT | P=0.580N P=0.090 | P=0.560 P=0.477 |
|=================================================================================================================================|
| |
|All Organs |
| Malignant and Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 26/60 (43%) 42/60 (70%) 54/60 (90%) | 24/60 (40%) 37/59 (63%) 49/59 (83%) |
|ADJUSTED (b) | 45.4% 92.6% 100.0% | 41.8% 73.8% 95.8% |
|TERMINAL (d) | 14/45 (31%) 16/19 (84%) 10/10 (100%) | 14/47 (30%) 16/28 (57%) 15/17 (88%) |
|FIRST INCIDENCE (DAYS) | 244 145 231 | 184 106 197 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P<0.001 ** P<0.001 ** P<0.001 ** | P<0.001 ** P<0.001 ** P<0.001 ** |
|INCIDENTAL TUMOR | P<0.001 ** P=0.025 * P=0.001 ** | P<0.001 ** P=0.092 P<0.001 ** |
|LOGISTIC REGRESSION | P<0.001 ** P=0.005 ** P<0.001 ** | P<0.001 ** P=0.037 * P<0.001 ** |
|COCHRAN-ARMITAGE | P<0.001 ** | P<0.001 ** |
|FISHER EXACT | P=0.003 ** P<0.001 ** | P=0.011 * P<0.001 ** |
|=================================================================================================================================|
DATE: 09/18/94 EXPERIMENT: 05212 TEST: 04 PAGE 8
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN 35( ) -- OXAZEPAM
TERMINAL SACRIFICE AT 57 WEEKS
(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Kaplan-Meier estimated lifetime tumor incidence after adjustment for
intercurrent mortality.
(d) Observed incidence at terminal kill.
(f) Beneath the control incidence are the P-values associated with the trend
test. Beneath the dosed group incidence are the P-values corresponding to
pairwise comparisons between the controls and that dosed group. The life
table analysis regards tumors in animals dying prior to terminal kill as
being (directly or indirectly) the cause of death. The incidental tumor
test regards these lesions as non-fatal. Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage
and Fisher's exact tests compare directly the overall incidence rates.
For all tests, a negative trend is indicated by "N".
(e) Value of Statistic cannot be computed.
(I) Interim sacrifice
(T) Terminal sacrifice
# Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).